[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"castleman-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:castleman-disease":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,56,88,112],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":34,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100271815","international-registry-for-patients-with-castleman-disease-100271815",false,"NCT02817997","International Registry for Patients With Castleman Disease","ACCELERATE (Advancing Castleman Care With an Electronic Longitudinal Registry, E-Repository, And Treatment\u002FEffectiveness Research): An International Registry for Patients With Castleman Disease","ACCELERATE","Inclusion Criteria:\n\n* Person of any age\n* Have a reference pathology report suggesting \"Castleman disease\" not limited to cutaneous involvement only that can be uploaded\n* Be able to provide electronic informed consent, as per local regulations\n* Deceased patients may also be enrolled when a reference pathology report suggesting \"Castleman disease\" can be supplied or when the ART is able to locate and upload such a pathology report.\n\nExclusion Criteria:\n\n* Because this registry is designed to provide as wide a picture of routine clinical practice as possible, inclusion criteria are set deliberately wide and there are no exclusion criteria.","ALL",{"count":19,"type":20},1000,"ESTIMATED","10 Years","OBSERVATIONAL","The purpose of this study is to collect clinical, laboratory, and patient survey data from patients with Castleman disease to improve understanding, diagnosis, and treatment of the disease. Funding source - FDA OOPD.",[25,26,27,28,29,30,31,32,33],"Castleman Disease","Castleman's Disease","Giant Lymph Node Hyperplasia","Angiofollicular Lymph Hyperplasia","Angiofollicular Lymph Node Hyperplasia","Angiofollicular Lymphoid Hyperplasia","GLNH","Hyperplasia, Giant Lymph Node","Lymph Node Hyperplasia, Giant",[35,36,37,38,39,40,26,28,41,42],"patient registry","ACCELERATE study","CD","MCD","iMCD","Castleman","multicentric Castleman's disease","multicentric Castleman disease","RECRUITING","2026-02-27",{"date":46,"type":47},"2026-03-03","ACTUAL",{"date":49,"type":4},"2016-10",{"date":51,"type":20},"2027-09",{"name":53,"class":54},"University of Pennsylvania","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":64,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100454682","autoinflammatory-disease-alliance-registry-aida-100454682","NCT05200715","AutoInflammatory Disease Alliance Registry (AIDA)","Development of an International Multicenter Registry of Patients With Monogenic and Polygenic Autoinflammatory Diseases Aimed at Clinical and Therapeutical Data Collection and Analysis","AIDA","Inclusion Criteria:\n\n* to be diagnosed with a monogenic AID according to the clinical phenotype and the detection of a confirmative genotype;\n* to be diagnosed with clinical familial Mediterranean fever or Behçet's disease or Still disease or PFAPA syndrome or Schnitzler's disease or CRMO according to the corresponding clinical diagnostic and\u002For classification criteria;\n* to be diagnosed with undifferentiated systemic AID;\n* to be diagnosed with non-infectious uveitis according to the standardization for uveitis nomenclature (SUN) criteria;\n* to be diagnosed with anterior or posterior non-infectious scleritis;\n* to be diagnosed with spondyloarthritis according to ASAS and\u002For New York criteria;\n* to be diagnosed with Castleman disease;\n\nExclusion Criteria:\n\n\\- informed consent\u002Fassent not provided by the patient and\u002For his\u002Fher legal representative.",{"count":65,"type":20},3500,"Autoinflammatory diseases (AID) are clinical entities characterized by recurrent inflammatory attacks in absence of infection, neoplasm or deregulation of the adaptive immune system. Among them, hereditary periodic syndromes, also known as monogenic AID, represent the prototype of this disease group, caused by mutations in genes involved in the regulation of innate immunity, inflammation and cell death. Based on recent experimental acquisitions in the field of monogenic AID, several immunologic disorders have been reclassified as polygenic\u002Fmultifactorial AID, sharing pathogenetic and clinical features with hereditary periodic fevers. This has paved the way to new treatment targets for patients suffering from rare diseases of unknown origin, including Behçet's disease, Still disease, Schnitzler's disease, PFAPA (periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis) syndrome, chronic recurrent multifocal osteomyelitis (CRMO), non-infectious uveitis and scleritis. Gathering information on such rare conditions is made difficult by the small number of patients, along with the difficulty of obtaining an accurate diagnosis in non-specialized clinical settings.\n\nIn this context, the AIDA project promotes international collaboration among clinical centres to develop a permanent registry aimed at collecting demographic, genetic, clinical and therapeutic data of patients affected by monogenic and polygenic AID, in order to expand the current knowledge of these rare conditions.",[68,69,70,71,72,73,74,75,76,77,25],"Hereditary Autoinflammatory Diseases","Schnitzler Syndrome","Behcet Syndrome","PFAPA Syndrome","Still Disease","Autoinflammatory Syndrome, Unspecified","Uveitis","Scleritis","Vexas Syndrome","Spondyloarthritis (SpA)","2025-07-07",{"date":80,"type":47},"2025-07-10",{"date":82,"type":47},"2020-08-06",{"date":84,"type":20},"2030-08-06",{"name":86,"class":54},"University of Siena",112,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":95,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":98,"conditions":99,"keywords":100,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100571485","an-italian-multicenter-retrospective-observational-study-to-assess-effectiveness-and-safety-of-siltuximab-for-patients-with-castlemans-disease-treated-in-italy-in-a-real-life-context-100571485","NCT06720870","An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context","SilOs","Inclusion Criteria:\n\n1. Histologically confirmed diagnosis of R\u002FR MCD HIV and HHV-8 negative patients who underwent siltuximab in a real-life context from July 2016 till April 2022.\n2. Age ≥ 18 yearsatenrollment\n3. Signature of written informed consent (where applicable)\n\nExclusion Criteria:\n\n1\\. R\u002FR MCD patients who underwent siltuximab in a clinical trial context","18 Years",{"count":97,"type":20},65,"The study is a pilot, observational, retrospective, and (italian) multicenter study.\n\nThe study will involve the collection of patient data from medical records for patients with Multicentric Castelman Disease Relapsed\u002FRefractory who received treatment with at least one dose of siltuximab, as part of standard of care in a real-life context, from July 2016 till April 2022 in 31selected italian centres.",[25],[101],"Siltuximab","2024-12-03",{"date":104,"type":47},"2024-12-06",{"date":106,"type":47},"2023-03-01",{"date":108,"type":20},"2025-01",{"name":110,"class":54},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",12,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":95,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":121,"phases":122,"briefSummary":124,"conditions":125,"keywords":126,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":4},"100565508","phase-2-nintedanib-treatment-in-unicentric-castleman-disease-100565508","NCT06643091","Nintedanib Treatment in Unicentric Castleman Disease","NUCastle","Inclusion Criteria:\n\n1. Age ≥ (equal to or greater than) 18 years\n2. Written informed consent\n3. Biopsy-proven diagnosis of hyaline-vascular Unicentric Castleman disease\n4. Unresectable or partially resectable UCD lesion or surgery refusal\n5. Available oral route\n6. Affiliated to National French social security system (registered or being a beneficiary of such a scheme)\n7. Women of childbearing potential should be advised and agree to avoid becoming pregnant while receiving treatment and to use highly effective contraceptive methods at initiation of, during and at least 3 months after the last dose of treatment; pregnancy testing must be conducted prior to treatment and during treatment as appropriate; breast-feeding should be discontinued during treatment\n8. In male patients, with WOCBP partner(s), willingness to use adequate contraceptive measures to prevent his partner from becoming pregnant during the study, prior to administration of the first dose of study treatment until 3 months after the last dose of study treatment\n\nExclusion Criteria:\n\n1. Synchronous Follicular Dendritic Cell sarcoma\n2. Known hypersensitivity to nintedanib, soy or peanut or to any of the excipients of the experimental drug, or known hypersensitivity to the auxiliary drugs listed or to any of their excipients.\n3. For women of childbearing age: negative serum or urine pregnancy test at inclusion and confirmed each month during the study, up to 3 months after the last dose.\n4. Inability to obtain informed consent\n5. Patients under legal protection\n6. Liver transaminases (AST and\u002For ALT) \\>3N\n7. End-stage liver disease (Child B or C cirrhosis)\n8. End-stage renal failure (CrCl\\<30 mL\u002Fmin)\n9. Severe hemorrhagic or thromboembolic events in the past 6 months\n10. Uncontrolled systemic illness such as chronic heart failure, unstable angina, hypertension; history of myocardial infarction or stroke or aneurysm\n11. Major injuries in the 10 days prior to start of the study, or Recent surgery with inadequate wound healing, or Abdominal surgery in the past 4 weeks.\n12. Severe pulmonary hypertension\n13. Bleeding risk, any of the following:\n\n    1. Known genetic predisposition to bleeding.\n    2. Patients who require\n\n1\\. Fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, direct thrombin inhibitors, heparin, hirudin) 2. High dose antiplatelet therapy corresponding to a combination of two anti-platelet aggregation treatment (aspirin + an Inhibitor of P2Y12 receptor) 14. Contraindication to the experimental drug or auxiliary drugs listed 15. Patients under guardianship or curatorship and protected adults or unable to consent 16. Enrollment in another interventional study (ongoing at the time of inclusion)",{"count":120,"type":20},13,"INTERVENTIONAL",[123],"PHASE2","Unicentric Castleman Disease (UCD) is a rare non-malignant localised disease involving one or more lymph nodes, associating germinal centre atrophy, mantle zone thickening and intense vascular proliferation penetrating the germinal centres. Patients usually seek medical attention because of a localised, sometimes compressive, lymph node or the development of life-threatening autoimmune complications (paraneoplastic pemphigus or PNP or myasthenia gravis or MG). The best treatment option is complete surgical excision, but it has been recently demonstrated that up to half of the patients cannot undergo surgery. In these patients, an efficient medical approach needs be defined, as no current medical treatment has demonstrated to lower morbidity and mortality. The cause of UCD is currently unknown and current data favour a scenario of stromal impairment leading to the loss of lymph node architecture rather than one of a primary hematopoietic disease. UCD lesions are often associated with synchronous follicular dendritic cell (FDC) proliferation and can sometimes evolve towards a true FDC sarcoma (FDCS), indicating a possible role for FDC, a germinal centre stromal cell component, in UCD pathogenesis. A recurrent somatic activating mutation in PDGFRB (p.N666S) has been recently described in the CD45 negative (non-hematopoietic) compartment of up to 17% UCD specimens. Moreover, activation of the VEGFR pathway is thought to play a role in the development of the disease, especially in the increased vascularity characteristic of the UCD lesion.\n\nNintedanib is a commercially available tyrosine-kinase inhibitor targeting PDGF, VEGF and FGF receptors. The drug has obtained European Market Authorization in 2015 for the treatment of Non-Small Cell Lung Cancer and Idiopathic Pulmonary Fibrosis with a satisfactory safety profile. The hypothesis is that nintedanib could benefit patients with unresectable or partially resectable UCD.",[25],[127],"Castleman disease","NOT_YET_RECRUITING","2024-10-14",{"date":131,"type":47},"2024-10-15",{"date":133,"type":20},"2024-11-01",{"date":135,"type":20},"2030-09-01",{"name":137,"class":54},"Assistance Publique - Hôpitaux de Paris"]